2-氯乙基甲基 1,4-二氢-2,6-二甲基-4-(3-硝基苯基)吡啶-3,5-二羧酸酯 | 54527-89-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯乙基甲基 1,4-二氢-2,6-二甲基-4-(3-硝基苯基)吡啶-3,5-二羧酸酯
• 中文别名: 2-氯乙基甲基1,4-二氢-2,6-二甲基-4-(3-硝基苯基)吡啶-3,5-二羧酸酯
• 英文名称: 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(2-chloroethyl)ester-5-methyl ester
• 英文别名: 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl ester 2-chloroethyl ester；2-chloroethyl 5-carbomethoxy-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate；2-chloroethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-pyridine-3,5-dicarboxylate；2-Chloroethyl Methyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate；2-Chloroethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate；2-chloroethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate；5-O-(2-chloroethyl) 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 54527-89-8
• 化学式: C₁₈H₁₉ClN₂O₆
• 分子量: 394.812
• InChiKey: HFLGCPOPFWAWDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-氯乙基甲基 1,4-二氢-2,6-二甲基-4-(3-硝基苯基)吡啶-3,5-二羧酸酯 在 sodium hydroxide 、 硝酸 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-hydroxyethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
  参考文献：
  名称：

  Meyer; Wehinger; Bossert, Arzneimittel-Forschung/Drug Research, 1983, vol. 33, # 1, p. 106 - 112

  摘要：

  DOI：
• 作为产物：
  描述：

  2-chloroethyl 2-(3-nitrobenzylidene)acetoacetate 生成 2-氯乙基甲基 1,4-二氢-2,6-二甲基-4-(3-硝基苯基)吡啶-3,5-二羧酸酯
  参考文献：
  名称：

  TANAKA, TATSUYOSHI;NAGAMI, KAZUYOSHI;TAMADA, SHIGEHARU;NAKAGAWA, KAZUYUKI

  摘要：

  DOI：

文献信息

• 1,4-Dihydropyridine derivatives
  申请人：FUJIREBIO INC.

  公开号：EP0320984A3

  公开（公告）日：1989-12-27

  1,4-Dihydropyridine derivatives of the formula (I) having vasodilative activity and inhibitory activity on platelet aggregation: wherein Ar¹ represents an aromatic hydrocarbon group or heterocyclic group which may have at least one substituent; R¹ represents a hydrocarbon group which may have at least one substituent; A and B each represent a hydrocarbon group which may have at least one substituent, in which any of the carbon atoms in the main chain thereof may be replaced by a nitrogen atom or an oxygen atom; Ar² represents an aromatic hydrocarbon group or heterocyclic group; Ar³ represents a heterocyclic group which may have at least one substituent; and n is 0 or 1.

  具有扩血管活性和抑制血小板聚集活性的式(I)的1,4-二氢吡啶衍生物： 其中Ar¹代表一个芳香烃基或杂环基，可能具有至少一个取代基；R¹代表一个可能具有至少一个取代基的碳氢基团；A和B分别代表一个可能具有至少一个取代基的碳氢基团，在其中主链的任何碳原子可以被氮原子或氧原子取代；Ar²代表一个芳香烃基或杂环基；Ar³代表一个可能具有至少一个取代基的杂环基；n为0或1。
• 1,4-dihydropyridine derivatives, and pharmaceutical compositions
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US04757071A1

  公开（公告）日：1988-07-12

  2,6-Dimethyl-4-(2- or 3-substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid diesters, having vasodilating and blood pressure lowering effects, in the ester moiety at the 3-position of which a heterocyclic group is linked to an alkylene group through an ester bond (carbonyloxy group). The diesters are used for treatment of cardiac diseases, cerebrovascular diseases and hypertension.

  2,6-二甲基-4-(2-或3-取代苯基)-1,4-二氢吡啶-3,5-二羧酸二酯具有扩张血管和降低血压的作用，在其酯基中，异环群通过酯键（羰氧基团）连接到烷基上的3-位。这些二酯用于治疗心脏疾病、脑血管疾病和高血压。
• Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters
  申请人：Bristol-Myers Company

  公开号：US04755512A1

  公开（公告）日：1988-07-05

  A series of 1,4-dihydropyridin-3,5-yl dicarboxylic acid amides and esters incorporating an arylpiperazinylalkyl moiety have been prepared possessing the general formula ##STR1## wherein R.sup.4 is cycloalkyl, aryl or hetaryl, generally with electronwithdrawing substituents; R.sup.2 and R.sup.6 are lower alkyl, alkanol, alkoxyalkyl, or alkylaminoalkyl; R.sup.5 is R.sup.2 or arylpiperazinylalkyl; X is 0 or NH; Y is lower alkylene, alkoxyalkylene, alkylaminoalkylene; and Z is phenyl, substituted phenyl, pyridinyl, substituted pyridinyl, or pyrimidinyl. Compounds of this series demonstrate activity as calcium and alphaadrenergic blockers in in vitro testing and antihypertensive, antiischemic, and platelet function inhibiting actions in in vivo screens.

  已翻译完成： 一系列包含芳基哌嗪基烷基基团的1,4-二氢吡啶-3,5-二羧酸酰胺和酯已经合成，具有一般化学式##STR1## 其中R.sup.4为环烷基、芳基或杂芳基，通常带有电子吸引基团；R.sup.2和R.sup.6为较低的烷基、烷醇、烷氧基烷基或烷基氨基烷基；R.sup.5为R.sup.2或芳基哌嗪基烷基；X为0或NH；Y为较低的烷基、烷氧基烷基、烷基氨基烷基；Z为苯基、取代苯基、吡啶基、取代吡啶基或嘧啶基。该系列化合物在体外测试中表现出作为钙通道和α肾上腺素受体拮抗剂的活性，并且在体内筛选中显示出抗高血压、抗缺血和抑制血小板功能的作用。
• 3,5-Diacyl-4-aryl-1,4 dihydropyridine derivatives, their uses and
  申请人：Ciba-Geigy Corporation

  公开号：US04853393A1

  公开（公告）日：1989-08-01

  Compounds of the formula ##STR1## in which R represents a carbocyclic or heterocyclic aryl radical, R.sub.1 represents lower alkyl, one of the groups R.sub.2 and R.sub.3 represents lower alkyl and the other represents lower alkyl, cyano or amino, X represents oxygen or the group --NH--, and Alk represents lower alkylene which separates the group X from the ring nitrogen atom by at least two carbon atoms, Y represents the group --CHOH-- or --(C.dbd.O)--, and Ar.sub.1 represents a monocyclic aryl or heteroaryl radical, Ar.sub.1 being other than unsubstituted phenyl if R.sub.1, R.sub.2 and R.sub.3 each represents lower alkyl, X represents oxygen, Alk represents straight-chain alkylene having from 2 to 4 carbon atoms, Y represents the group --(C.dbd.O)-- and R has the meaning given, and salts thereof have cardiovascular, especially coronary-dilatory and antihypertensive properties.

  式为##STR1##的化合物，其中R代表碳环或杂环芳基基团，R.sub.1代表较低的烷基，R.sub.2和R.sub.3中的一个代表较低的烷基，另一个代表较低的烷基、氰基或氨基，X代表氧或--NH--基团，Alk代表较低的烷基，将基团X与环氮原子隔开至少两个碳原子，Y代表--CHOH--或--(C.dbd.O)--基团，Ar.sub.1代表单环芳基或杂环芳基基团，如果R.sub.1、R.sub.2和R.sub.3每个代表较低的烷基，X代表氧，Alk代表具有2至4个碳原子的直链烷基，Y代表--(C.dbd.O)--基团，R具有所给的含义，以及其盐具有心血管、特别是冠脉扩张和降压作用。
• Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions
  申请人：Jobdevairakkam Christopher N.

  公开号：US20080125595A1

  公开（公告）日：2008-05-29

  A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water. An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol. An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component. A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

  一种制备1,4-二氢吡啶盐（如盐酸尼卡地平）的稳定无菌溶液的工艺，该工艺在酸性水介质中进行。溶液中存在L-精氨酸，可增强盐的溶解度，而盐在水中溶解度较差。该无菌溶液为水溶性、注射用的等渗溶液，pH值约为3.5-3.6，主要由盐酸尼卡地平、L-精氨酸和糖醇组成。 一种改进的单锅制造工艺，用于通过使用超过其他反应物（氨基丙烯酸酯和乙酰乙酸酯）的摩尔当量的醛类来获得非对称的1,4-二氢吡啶。该反应可以在溶剂中进行，溶剂的量为任何一个组分的20倍。 一种将尼卡地平盐酸的一种多晶形式（A型）转变为另一种多晶形式（B型）的工艺，以及将B型转变为A型的单独工艺。